Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807350 · ClinicalTrials.gov registry record · NA
Trial of Overminus Spectacle Therapy for Intermittent Exotropia
A NA study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- NA
- Development phase
- 386
- Enrollment target
NCT02807350: Completed NA study, sponsored by Jaeb Center for Health Research.
NCT02807350 is a NA study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 386 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807350, a NA study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 386 participants
- Enrollment target
Study Summary
The main objectives of this randomized trial comparing overminus lens treatment to non-overminus (spectacles without overminus or spectacles with plano lenses) are to determine: * The long-term on-treatment effect of overminus treatment on distance intermittent exotropia (IXT) control score. * The off-treatment effect of overminus treatment on distance IXT control score (following weaning and 3 months off treatment).
Primary Outcome
A comparison of mean control of the distance exodeviation (average of 3 measurements over the exam) between the 2.50 diopters (D) overminus group and the non-overminus group (spectacles without overminus or no spectacles) at 12 months. The Office Control Score provides a rating of exodeviation control on a 0 to 5 scale, in subjects with intermittent exotropia. Scores 3 to 5 reflect the proportion of time a spontaneous manifest exotropia is present during 30 seconds of observation (\<50% score 3;
Interventions
- DEVICE Overminus treatment
- DEVICE Non-overminus treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2017-01-16 |
| Est. Completion | 2022-02-15 |
| Phase | NA |
What the finished NCT02807350 record still lists
NCT02807350 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Overminus treatment is the first listed.
NCT02807350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02807350 about?
NCT02807350 is a clinical study titled "Trial of Overminus Spectacle Therapy for Intermittent Exotropia". The main objectives of this randomized trial comparing overminus lens treatment to non-overminus (spectacles without overminus or spectacles with plano lenses) are to determine: * The long-term on-treatment effect of overminus treatment on distance intermittent exotropia (IXT) control score. * The ...
What is the current status of trial NCT02807350?
This trial is currently completed. It is a NA study. The enrollment target is 386 participants. The study started on 2017-01-16. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT02807350?
The interventions under investigation include: Overminus treatment (DEVICE), Non-overminus treatment (DEVICE).
Who is sponsoring clinical trial NCT02807350?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02807350's enrollment target sits among peer trials
386 271st of 2000 higher than 1,730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI